Brexpiprazole, OPC-34712
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Agitation Associated With
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Trial Timeline
Sep 1, 2013 → Mar 1, 2017
NCT ID
NCT01922258About Brexpiprazole, OPC-34712
Brexpiprazole, OPC-34712 is a phase 3 stage product being developed by Lundbeck for Agitation Associated With. The current trial status is completed. This product is registered under clinical trial identifier NCT01922258. Target conditions include Agitation Associated With, Alzheimer's Disease, Alzheimer's Type.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01922258 | Phase 3 | Completed |
Competing Products
20 competing products in Agitation Associated With